CDT
HEALTHCAREConduit Pharmaceuticals Inc.
What's Moving CDT Today?
No stock-specific AI insight has been generated for CDT yet. Check back soon — insights are generated from recent news analysis.
Market Briefings featuring CDT
52-Week Range
$1.13
Fundamentals
Trading
CDT News
24 articles- CDT Equity (CDT) large holders report zero ownership after June 18 salesStock Titan·Jun 24, 2026
- CDT Notes Strategic Investment into Sarborg and Expansion into Quantum ComputingYahoo Finance·Jun 18, 2026
- CDT Equity Secures $1.97 Million Convertible Note, Grants Lien and Issues 912,500 WarrantsTradingView·Jun 17, 2026
- CDT Equity Announces Debt Update and New Loan FacilityYahoo Finance·Jun 16, 2026
- Number of shareholders of CDT Equity Inc. – NASDAQ:CDTTWTradingView·Jun 13, 2026
- CDT Equity Inc. Announces Receipt of Nasdaq Deficiency LetterYahoo Finance·May 28, 2026
- CDT Announces Canadian Patent for AZD5904 in Male InfertilityYahoo Finance·May 27, 2026
- CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection StageYahoo Finance·May 11, 2026
- CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis MarketYahoo Finance·May 7, 2026
- CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering DiscussionsYahoo Finance·May 6, 2026
- CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven DiscoveryYahoo Finance·Apr 16, 2026
- What's Going On With CDT Equity Shares On Monday?Benzinga·Apr 13, 2026
- CDT Notes Sarborg Publication of PRISM Framework Expanding AIYahoo Finance·Apr 7, 2026
- CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent FilingsYahoo Finance·Mar 26, 2026
- CDT Equity Inc. Announces Reverse Stock SplitYahoo Finance·Mar 25, 2026
- CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing StrategyYahoo Finance·Mar 23, 2026
- CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of GrowthYahoo Finance·Mar 18, 2026
- CDT Notes Sarborg Expansion into Rare Disease Signature IntelligenceYahoo Finance·Mar 12, 2026
- CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature AgentYahoo Finance·Mar 5, 2026
- CDT Positions for Transformational GrowthYahoo Finance·Mar 4, 2026
- CDT Equity Notes Sarborg Expansion into Bacteria and AgrochemicalsYahoo Finance·Feb 24, 2026
- CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset StrategyYahoo Finance·Feb 20, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Jan 2, 2026
- CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing StrategyYahoo Finance·Aug 26, 2025
All 24 articles loaded
Price Data
52-Week Range
$1.13
Fundamentals
Trading
About Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage biopharmaceutical company dedicated to developing advanced therapies for oncology and rare diseases, addressing significant unmet medical needs. Leveraging its proprietary drug delivery technology, Conduit strives to enhance the efficacy and safety profiles of existing treatments, ultimately improving patient outcomes while minimizing adverse effects. Backed by an experienced management team and an emphasis on strategic partnerships, the company is strategically poised to advance its innovative product pipeline, aiming to make a transformative impact in the healthcare sector.